Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)‘s stock had its “outperform” rating restated by equities researchers at Leerink Swann in a note issued to investors on Tuesday. They currently have a $94.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $85.00. Leerink Swann’s price target suggests a potential upside of 22.75% from the company’s previous close.

Other research analysts have also issued reports about the stock. Jefferies Group restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Sunday, July 17th. Cowen and Company restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 15th. Canaccord Genuity restated a “buy” rating and set a $120.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 15th. Credit Suisse Group AG restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 12th. Finally, JMP Securities reiterated a “buy” rating and issued a $84.00 price target (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $97.89.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up 1.751% on Tuesday, reaching $77.921. 149,424 shares of the company’s stock were exchanged. Ultragenyx Pharmaceutical has a 12 month low of $46.52 and a 12 month high of $117.12. The firm’s 50-day moving average price is $67.24 and its 200 day moving average price is $62.97. The company’s market cap is $3.07 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.02. During the same period in the prior year, the business posted ($0.83) EPS. Equities research analysts predict that Ultragenyx Pharmaceutical will post ($5.93) EPS for the current fiscal year.

In related news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $50.85, for a total value of $1,017,000.00. Following the completion of the transaction, the chief executive officer now owns 513,597 shares of the company’s stock, valued at approximately $26,116,407.45. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sunil Agarwal sold 649 shares of the stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $52.68, for a total transaction of $34,189.32. The disclosure for this sale can be found here. Insiders own 10.10% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP increased its position in shares of Ultragenyx Pharmaceutical by 79.9% in the first quarter. Wellington Management Group LLP now owns 4,132,430 shares of the biopharmaceutical company’s stock valued at $261,625,000 after buying an additional 1,835,196 shares during the last quarter. Norges Bank bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $34,393,000. State Street Corp increased its position in shares of Ultragenyx Pharmaceutical by 30.6% in the first quarter. State Street Corp now owns 1,284,324 shares of the biopharmaceutical company’s stock valued at $81,315,000 after buying an additional 300,901 shares during the last quarter. Pictet Asset Management Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 2,459.6% in the second quarter. Pictet Asset Management Ltd. now owns 194,527 shares of the biopharmaceutical company’s stock valued at $14,220,000 after buying an additional 186,927 shares during the last quarter. Finally, Lord Abbett & CO. LLC increased its position in shares of Ultragenyx Pharmaceutical by 116.3% in the second quarter. Lord Abbett & CO. LLC now owns 337,153 shares of the biopharmaceutical company’s stock valued at $16,490,000 after buying an additional 181,270 shares during the last quarter. 93.06% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.